Coherus Oncology
CHRS
137 hedge funds and large institutions have $198M invested in Coherus Oncology in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 56 reducing their positions, and 42 closing their positions.
3% less call options, than puts
Call options by funds: $666K | Put options by funds: $684K
1.52% less ownership
Funds ownership: 75.66% → 74.14% (-1.5%)
12% less funds holding
Funds holding: 156 → 137 (-19)
29% less capital invested
Capital invested by funds: $278M → $198M (-$80.6M)
32% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 56
45% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 42
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$24.6M |
| 2 |
TC
Tejara Capital
London,
United Kingdom
|
+$2.6M |
| 3 |
Goldman Sachs
New York
|
+$2.16M |
| 4 |
CC
Clearline Capital
New York
|
+$1.93M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pictet Asset Management
Carouge,
Switzerland
|
-$8.26M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$5.38M |
| 3 |
Millennium Management
New York
|
-$3.9M |
| 4 |
Morgan Stanley
New York
|
-$3.63M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.49M |
CHRS Hedge Fund Activity: Q1 2024 in Review
137 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2024, worth a combined $198M — down 29% from $278M a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of CHRS and 23 opened new positions — a net loss of 19 holders — while 56 trimmed existing stakes and 38 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $24.6M. The largest seller was Pictet Asset Management, exiting entirely with an estimated $8.26M sold.
- 137 institutional investors held Coherus Oncology (CHRS) as of Q1 2024, down from 156 in Q4 2023.
- Funds reported $198M of Coherus Oncology stock for Q1 2024, down 29% quarter-over-quarter.
- 23 funds opened new Coherus Oncology positions in Q1 2024 and 42 closed out, a net change of -19 holders.
- The largest Coherus Oncology buyer in Q1 2024 was Rubric Capital Management (New York), an estimated $24.6M added.
- The largest Coherus Oncology seller in Q1 2024 was Pictet Asset Management, an estimated $8.26M sold.
Based on aggregated 13F filings for Q1 2024.